IQVIA debuts clinical data analytics intelligence platform
IQVIA has debuted a clinical data analytics intelligence platform to accelerate vaccine development and drug discovery. Read More
VBI touts positive preclinical COVID-19 vaccine data
Preclinical data suggest positive results from a COVID-19 vaccine candidate based on enveloped viruslike particle technology from VBI Vaccines (VBI). Read More
Immunome SARS-CoV-2 antibody cocktail neutralizes variants
Immunome said that preclinical testing shows that its IMM-BCP-01 antibody cocktail neutralizes SARS-CoV-2 variants of concern. Read More
Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine. Read More
Following review, FDA lifts J&J COVID-19 vaccine pause
Johnson & Johnson's COVID-19 vaccinations are set to resume in the U.S. following a decision by the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention. Read More
Naturally occurring molecule helps SARS-CoV-2 evade neutralizing antibodies
Researchers have identified naturally occurring molecules that are created from the breakdown of hemoglobin and block the binding of a subset of human antibodies to SARS-CoV-2. The discovery, published in Science Advances on April 22, may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus. Read More
Inovio will not conduct phase III COVID-19 vaccine trial in U.S.
Inovio announced it is planning for a phase III trial outside of the U.S. for its INO-4800 COVID-19 vaccine candidate after the U.S. Department of Defense discontinued funding for the candidate. Read More
Cell-free technique could enable on-demand vaccine production
A new cell-free synthetic biology technique that increases the volume of membrane components in the manufacture of conjugate vaccines can significantly improve the efficiency of vaccine production, according to a new method published in Nature Communications on April 22. The technology could enable on-site production of vaccines and therapies, enabling them to be more efficiently distributed in areas where they are most needed. Read More
NIH grants Vaxess $2.9M to develop vaccine patch
Vaxess Technologies announced it has received a $2.9 million grant from the National Institute of Allergy and Infectious Diseases, an agency of the U.S. National Institutes of Health (NIH), to evaluate and commercialize a method for delivering vaccines through a next-generation, sustained-release intradermal microneedle patch. Read More
Valneva begins phase III COVID-19 vaccine trial
Valneva announced it has initiated a phase III trial to evaluate its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company's Cov-Compare trial will pit VLA2001 against AstraZeneca's conditionally approved vaccine, Vaxzevria, in a comparative immunogenicity trial. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter